相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Personalized Dietary Management of Overweight and Obesity Based on Measures of Insulin and Glucose
Mads F. Hjorth et al.
ANNUAL REVIEW OF NUTRITION, VOL 38 (2018)
Sotagliflozin in Combination With Optimized Insulin Therapy in Adults With Type 1 Diabetes: The North American inTandem1 Study
John B. Buse et al.
DIABETES CARE (2018)
SGLT2 Inhibitors in Combination Therapy: From Mechanisms to Clinical Considerations in Type 2 Diabetes Management
Michael J. B. van Baar et al.
DIABETES CARE (2018)
Weight loss associated with sodium-glucose cotransporter-2 inhibition: a review of evidence and underlying mechanisms
P. C. Lee et al.
OBESITY REVIEWS (2018)
SGLT2 Inhibitors in Type 2 Diabetes Management: Key Evidence and Implications for Clinical Practice
John Wilding et al.
DIABETES THERAPY (2018)
Renal, metabolic and cardiovascular considerations of SGLT2 inhibition
Ralph A. DeFronzo et al.
NATURE REVIEWS NEPHROLOGY (2017)
Duodenal Sodium/Glucose Cotransporter 1 Expression Under Fasting Conditions Is Associated With Postload Hyperglycemia
Teresa Vanessa Fiorentino et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2017)
Mechanisms, Pathophysiology, and Management of Obesity
Steven B. Heymsfield et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes
Satish K. Garg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Empagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitus
Ian J. Neeland et al.
DIABETES & VASCULAR DISEASE RESEARCH (2016)
Glucagon increases energy expenditure independently of brown adipose tissue activation in humans
V. Salem et al.
DIABETES OBESITY & METABOLISM (2016)
An overview of the effect of sodium glucose cotransporter 2 inhibitor monotherapy on glycemic and other clinical laboratory parameters in type 2 diabetes patients
Yaowen Wang et al.
THERAPEUTICS AND CLINICAL RISK MANAGEMENT (2016)
Energy Balance After Sodium-Glucose Cotransporter 2 Inhibition
Giulia Ferrannini et al.
DIABETES CARE (2015)
Long-term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add-on therapy to metformin in patients with type 2 diabetes: 4-year data
S. Del Prato et al.
DIABETES OBESITY & METABOLISM (2015)
Latest approaches for the treatment of obesity
V. Margaret Jackson et al.
EXPERT OPINION ON DRUG DISCOVERY (2015)
Accelerated Intestinal Glucose Absorption in Morbidly Obese Humans: Relationship to Glucose Transporters, Incretin Hormones, and Glycemia
Nam Q. Nguyen et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2015)
Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline
Caroline M Apovian et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2015)
Greater Dose-Ranging Effects on A1C Levels Than on Glucosuria With LX4211, a Dual Inhibitor of SGLT1 and SGLT2, in Patients With Type 2 Diabetes on Metformin Monotherapy
Julio Rosenstock et al.
DIABETES CARE (2015)
Canaglif lozin Provides Durable Glycemic Improvements and Body Weight Reduction Over 104 Weeks Versus Glimepiride in Patients With Type 2 Diabetes on Metformin: A Randomized, Double-Blind, Phase 3 Study
Lawrence A. Leiter et al.
DIABETES CARE (2015)
Pharmacodynamics, Efficacy and Safety of Sodium-Glucose Co-Transporter Type 2 (SGLT2) Inhibitors for the Treatment of Type 2 Diabetes Mellitus
Andre J. Scheen
DRUGS (2015)
Localizations of Na+-D-glucose cotransporters SGLT1 and SGLT2 in human kidney and of SGLT1 in human small intestine, liver, lung, and heart
Ivana Vrhovac et al.
PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY (2015)
Long-term Drug Treatment for Obesity A Systematic and Clinical Review
Susan Z. Yanovski et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2014)
Effects of GLP-1 on appetite and weight
Meera Shah et al.
REVIEWS IN ENDOCRINE & METABOLIC DISORDERS (2014)
Improved glycemic control in mice lacking Sglt1 and Sglt2
David R. Powell et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2013)
Pharmacology, Physiology, and Mechanisms of Incretin Hormone Action
Jonathan E. Campbell et al.
CELL METABOLISM (2013)
Effects of LX4211, a Dual SGLT1/SGLT2 Inhibitor, Plus Sitagliptin on Postprandial Active GLP-1 and Glycemic Control in Type 2 Diabetes
Brian Zambrowicz et al.
CLINICAL THERAPEUTICS (2013)
Molecular mechanisms of incretin hormone secretion
Marina Ezcurra et al.
CURRENT OPINION IN PHARMACOLOGY (2013)
Novel Hypothesis to Explain Why SGLT2 Inhibitors Inhibit Only 30-50% of Filtered Glucose Load in Humans
Muhammad A. Abdul-Ghani et al.
DIABETES (2013)
Global obesity: trends, risk factors and policy implications
Vasanti S. Malik et al.
NATURE REVIEWS ENDOCRINOLOGY (2013)
Emerging combinatorial hormone therapies for the treatment of obesity and T2DM
Sharon A. Sadry et al.
NATURE REVIEWS ENDOCRINOLOGY (2013)
Use of Prescription Antiobesity Drugs in the United States
Christian Hampp et al.
PHARMACOTHERAPY (2013)
LX4211 Increases Serum Glucagon-Like Peptide 1 and Peptide YY Levels by Reducing Sodium/Glucose Cotransporter 1 (SGLT1)-Mediated Absorption of Intestinal Glucose
David R. Powell et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2013)
LX4211, a Dual SGLT1/SGLT2 Inhibitor, Improved Glycemic Control in Patients With Type 2 Diabetes in a Randomized, Placebo-Controlled Trial
B. Zambrowicz et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2012)
Efficacy and Safety of SGLT2 Inhibitors in the Treatment of Type 2 Diabetes Mellitus
Muhammad A. Abdul-Ghani et al.
CURRENT DIABETES REPORTS (2012)
Outstanding Scientific Achievement Award Lecture 2011: Defeating Diabesity The Case for Personalized Combinatorial Therapies
Matthias H. Tschoep et al.
DIABETES (2012)
Neuropeptide Y, peptide YY and pancreatic polypeptide in the gut-brain axis
Peter Holzer et al.
NEUROPEPTIDES (2012)
The FDA's Assessment of Two Drugs for Chronic Weight Management
Eric Colman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials
Tina Vilsboll et al.
BMJ-BRITISH MEDICAL JOURNAL (2012)
Neuropsychiatric Adverse Effects of Centrally Acting Antiobesity Drugs
Pradeep J. Nathan et al.
CNS NEUROSCIENCE & THERAPEUTICS (2011)
Safety, Pharmacokinetic, and Pharmacodynamic Profiles of Ipragliflozin (ASP1941), a Novel and Selective Inhibitor of Sodium-Dependent Glucose Co-Transporter 2, in Patients with Type 2 Diabetes Mellitus
Sherwyn L. Schwartz et al.
DIABETES TECHNOLOGY & THERAPEUTICS (2011)
Role of Sodium-Glucose Cotransporter 2 (SGLT 2) Inhibitors in the Treatment of Type 2 Diabetes
Muhammad A. Abdul-Ghani et al.
ENDOCRINE REVIEWS (2011)
Biology of Human Sodium Glucose Transporters
Ernest M. Wright et al.
PHYSIOLOGICAL REVIEWS (2011)
Cardiovascular Risk-Benefit Profile of Sibutramine
A. J. Scheen
AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS (2010)
GIP: No Longer the Neglected Incretin Twin?
Rohit N. Kulkarni
SCIENCE TRANSLATIONAL MEDICINE (2010)
Dapagliflozin, a Novel, Selective SGLT2 Inhibitor, Improved Glycemic Control Over 2 Weeks in Patients With Type 2 Diabetes Mellitus
B. Komoroski et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies
Gary Whitlock et al.
LANCET (2009)
The Preventable Causes of Death in the United States: Comparative Risk Assessment of Dietary, Lifestyle, and Metabolic Risk Factors
Goodarz Danaei et al.
PLOS MEDICINE (2009)
分享论文
